Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q2 2018 · 10-Q
Revenue$3.68M$3.68Mno prior Q2 2017 on file Net Income-$31.22M-$31.22MN/M vs Q2 2017 EPS Diluted-$1.01-$1.01N/M vs Q2 2017 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
Operating Cash Flowderived-$21,833,000N/M Free Cash Flowderived-$22,185,000N/M Margins · derivedGross margin67.9%
Operating margin-869.9%
Net margin-849.2%
ended Jun 30, 2018 · filed Aug 3, 2018 · 34 d after period end